Release Date: 2024-06-10

Radiological Imaging in Liver Tumors: Diagnosis and Management Strategies

Ensar Turko (Author)

Release Date: 2024-06-10

Radiological imaging plays a pivotal role in the comprehensive management of liver tumors, encompassing diagnosis, treatment planning, and monitoring of therapeutic responses. Key imaging modalities utilized include ultrasonography (USG), computed tomography (CT), and magnetic resonance imaging (MRI), each offering distinct advantages and applications. Ultrasonography (USG): Ultrasonography is widely employed due to its accessibility, real-time imaging [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inThe Radiology of Cancer
    First Page161
    Last Page183
    DOIhttps://doi.org/10.69860/nobel.9786053359364.14
    Page Count23
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Radiological imaging plays a pivotal role in the comprehensive management of liver tumors, encompassing diagnosis, treatment planning, and monitoring of therapeutic responses. Key imaging modalities utilized include ultrasonography (USG), computed tomography (CT), and magnetic resonance imaging (MRI), each offering distinct advantages and applications.
    Ultrasonography (USG): Ultrasonography is widely employed due to its accessibility, real-time imaging capabilities, and cost-effectiveness. It is particularly valuable for monitoring benign liver lesions and for guiding interventions such as biopsies. However, its utility can be limited by operator-dependent variability, challenges in obese patients, and interference from bowel gas. USG is less effective in characterizing atypical liver tumors, necessitating complementary cross-sectional imaging for comprehensive evaluation.
    Computed Tomography (CT) and Magnetic Resonance Imaging (MRI):
    CT and MRI are indispensable for detailed characterization of liver lesions, leveraging multi-phase contrast-enhanced imaging to highlight vascular and structural features. In CT imaging, the arterial, portal venous, and equilibrium phases provide sequential insights into contrast uptake and washout patterns within tumors. MRI, particularly with hepatocyte-specific contrast agents like gadoxetic acid, enhances hepatocellular uptake visualization, aiding in the differentiation of hepatocellular carcinoma (HCC) from benign lesions and metastases.
    Benign Liver Tumors: Benign liver tumors include hemangiomas, focal nodular hyperplasia (FNH), hepatocellular adenomas (HCA), lipomas, angiomyolipomas, biliary hamartomas, and biliary cystadenomas. Each tumor type exhibits characteristic imaging features on CT and MRI, such as enhancement patterns, signal intensities on T1-weighted and T2-weighted sequences, and specific contrast agent uptake behaviors.
    Malignant Liver Tumors: Malignant liver tumors encompass primary hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), metastases from various primary sites, hepatoblastoma, hepatic angiosarcoma, epithelioid hemangioendothelioma (EHE), and embryonal sarcoma. These tumors present with distinct radiological characteristics, including vascular enhancement patterns, signal intensities on MRI sequences, and specific imaging findings such as ""wash-in/wash-out"" patterns in HCC and ""hypovascular"" features in ICC.
    Clinical Implications and Advances: Recent advancements in imaging techniques have significantly improved the sensitivity and specificity of liver tumor diagnosis. Techniques such as diffusion-weighted imaging (DWI) provide additional insights into tumor cellularity and microstructural properties, enhancing diagnostic accuracy. Moreover, the integration of advanced imaging protocols and contrast agents has enabled precise treatment planning and monitoring, ultimately improving patient outcomes.
    In conclusion, radiological imaging remains indispensable in the multidisciplinary approach to liver tumors, facilitating early detection, accurate diagnosis, and tailored treatment strategies based on comprehensive tumor characterization.

    Ensar Turko (Author)
    Assistant Professor, Van Yuzuncu Yil University
    https://orcid.org/0000-0001-7989-5668
    3Dr. Ensar TURKO graduated from the faculty of medicine in 2014. In 2020, he completed his specialization in radiology at Yüzüncü Yıl University. Since 2022, he has been working as a lecturer in the department of radiology at Yüzüncü Yıl University. He is especially interested in oncologic interventional radiology. He also works on diagnostic radiology of hepatobiliary oncologic diseases.

    • Venkatesh SK, Chandan V, Roberts LR. Liver masses: a clinical, radiologic, and pathologic perspective. Clinical Gastroenterology and Hepatology, 2014; 12(9), 1414-1429.

    • Leonhardt M, Keiser M, Oswald S, Kühn J, Jia J, Grube M, Kroemer HK, Siegmund W, Weitschies W. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos. 2010; 38(7):1024–1028.

    • Cogley JR, Miller FH. MR imaging of benign focal liver lesions. Radiologic Clinics, 2014;52(4), 657-682.

    • Watanabe A, Ramalho M, AlObaidy M, Kim HJ, Velloni FG, Semelka RC. Magnetic resonance imaging of the cirrhotic liver: An update. World journal of hepatology, 2015; 7(3), 468.

    • Matos AP, Velloni F, Ramalho M, AlObaidy M, Rajapaksha A, Semelka RC. Focal liver lesions: Practical magnetic resonance imaging approach. World journal of hepatology, 2015;7(16), 1987.

    • Sousa MS, Ramalho M, Herédia V, Matos AP, Palas J, Jeon Y H, Semelka RC. Perilesional enhancement of liver cavernous hemangiomas in magnetic resonance imaging. Abdominal imaging, 2014;39, 722-730.

    • LeGout JD, Bolan CW, Bowman AW, Caserta MP, Chen FK, Cox KL, Alexander LF. Focal nodular hyperplasia and focal nodular hyperplasia–like lesions. Radiographics, 2022; 42(4), 1043-1061.

    • Kinoshita M, Takemura S, Tanaka S, Hamano G, Ito T, Aota T, Koda M, Ohsawa M, Kubo S. Ruptured focal nodular hyperplasia observed during follow-up: a case report. Surg Case Rep 2017;3(1):44

    • Kim JV, Wu GY. Focal Nodular Hyperplasia: A Comprehensive Review with a Particular Focus on Pathogenesis and Complications. Journal of Clinical and Translational Hepatology, 2024;12(2), 182.

    • Yoneda N, Matsui O, Kitao A, Kozaka K, Kobayashi S, Sasaki M, Yoshida K, Inoue D, Minami T, Gabata T. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background. RadioGraph-ics 2016;36(7):2010–2027

    • Nault JC, Bioulac–Sage P, Zucman–Rossi J. Hepatocellular benign tumors—from molecular classification to personalized clinical care. Gastroenterology, 2013;144(5), 888-902.

    • Hussain SM, van den Bos IC, Dwarkasing RS, Kuiper JW, Den Hollander J. Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis. European radiology, 2006;16, 1873-1886.

    • Manenti G, Picchi E, Castrignanò A, Muto M, Nezzo M, Floris R. Liver lipoma: a case report. BJR case reports, 2016;3(2), 20150467.

    • Klompenhouwer AJ, Dwarkasing RS, Doukas M, Pellegrino S, Vilgrain V, Paradis V, Ijzermans JN. Hepatic angiomyolipoma: an international multicenter analysis on diagnosis, management and outcome. HPB, 2020;22(4), 622-629.

    • Sheikh AAE, Nguyen AP, Leyba K, Javed N, Shah S, Deradke A, Nguyen A. Biliary duct hamartomas: a systematic review. Cureus, 2022;14(5).

    • Bartolome MAH, Ruiz SF, Romero IM, Lojo BR, Prieto IR, Alvira LG, Esteban ML. Biliary cystadenoma. World journal of gastroenterology. 2009;15(28), 3573.

    • El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007;132(7), 2557-2576.

    • Zhao C, Dai H, Shao J, He Q, Su W, Wang P, Xiang S. Accuracy of various forms of contrast-enhanced MRI for diagnosing hepatocellular carcinoma: a systematic review and meta-analysis. Frontiers in Oncology, 2021;11, 680691.

    • Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology, 2014;273(1), 30-50.

    • Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Koh DM. Consensus report from the 8th international forum for liver magnetic resonance imaging. European radiology, 2020;30, 370-382.

    • Chartampilas E, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P. Current imaging diagnosis of hepatocellular carcinoma. Cancers, 2022;14(16), 3997.

    • Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. American Journal of Roentgenology, 2003;181(3), 819-827.

    • Kim MJ, Rhee H, Woo HY. A dichotomous imaging classification for cholangiocarcinomas based on new histologic concepts. European Journal of Radiology, 2019;113, 182-187.

    • Kim TH, Kim H, Joo I, Lee JM. Combined hepatocellular-cholangiocarcinoma: changes in the 2019 world health organization histological classification system and potential impact on imaging-based diagnosis. Korean Journal of Radiology, 2020; 21(10), 1115.

    • Nam JG, Lee JM, Joo I, Ahn SJ, Park JY, Lee KB, Han JK. Intrahepatic mass-forming cholangiocarcinoma: relationship between computed tomography characteristics and histological subtypes. Journal of computer assisted tomography, 2018;42(3), 340-349.

    • Kovač JD, Janković A, Đikić-Rom A, Grubor N, Antić A, Dugalić V. Imaging spectrum of intrahepatic mass-forming cholangiocarcinoma and its mimickers: How to differentiate them using MRI. Current Oncology, 2022;29(2), 698-723.

    • Kudo M, Izumi ., Kokudo N, Matsui O, Sakamoto M, Nakashima O. HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Digestive diseases, 2011; 29(3), 339-364.

    • Thian YL, Riddell AM, Koh DM. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer imaging, 2013;13(4), 567.

    • Donati OF, Fischer MA, Chuck N, Hunziker R, Weishaupt D, Reiner CS. Accuracy and confidence of Gd-EOB-DTPA enhanced MRI and diffusion-weighted imaging alone and in combination for the diagnosis of liver metastases. European journal of radiology, 2013;82(5), 822-828.

    • Shelmerdine SC, Roebuck DJ, Towbin AJ, McHugh K. MRI of paediatric liver tumours: how we review and report. Cancer Imaging, 2016;16, 1-10.

    • Bruegel M, Muenzel D, Waldt S, Specht K, Rummeny EJ. Hepatic angiosarcoma: cross-sectional imaging findings in seven patients with emphasis on dynamic contrast-enhanced and diffusion-weighted MRI. Abdominal imaging, 2013;38, 745-754.

    • Jang JK, Thomas R, Braschi-Amirfarzan M, Jagannathan JP. A review of the spectrum of imaging manifestations of epithelioid hemangioendothelioma. American Journal of Roentgenology, 2020;215(5), 1290-1298.

    • Gabor F, Franchi-Abella S, Merli L, Adamsbaum C, Pariente D. Imaging features of undifferentiated embryonal sarcoma of the liver: a series of 15 children. Pediatric radiology, 2016; 46, 1694-1704.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!